BlackRock Health Sciences Trust has seen some strong performance recently, yet still trades at a -7.8% discount to NAV, offering compelling value. BME removed its options-writing strategy, eliminating ...
BlackRock Health Sciences Trust is upgraded to a buy, benefiting from its shift to an equity-focused strategy and improved NAV growth prospects. BME offers an 8.3% monthly dividend yield, but coverage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results